The results collectively demonstrated that AZD7762 and OTX‐015 can synergistically suppress MYC levels and induce cell death in patient‐derived HCC models, highlighting the clinical value of concurrently inhibiting CHK1 and BRD4 in MYC‐deregulated HCC. This evidence concerns the gene BRD4 and hepatocellular carcinoma.